The DOI matches its Crossref record; 103 of the 104 references it cites were found in a registry or an index.
Repurposing of Benzimidazole Anthelmintic Drugs as Cancer Therapeutics
Open accessAbstract
Benzimidazoles have shown significant promise for repurposing as a cancer therapy. The aims of this review are to investigate the possibilities and limitations of the anti-cancer effects of benzimidazole anthelmintics and to suggest ways to overcome these limitations. This review included studies on the anti-cancer effects of 11 benzimidazoles. Largely divided into three parts, i.e., preclinical anti-cancer effects, clinical anti-cancer effects, and pharmacokinetic properties, we examine the characteristics of each benzimidazole and attempt to elucidate its key properties. Although many studies have demonstrated the anti-cancer effects of benzimidazoles, there is limited evidence regarding their effects in clinical settings. This might be because the clinical trials conducted using benzimidazoles failed to restrict their participants with specific criteria including cancer entities, cancer stages, and genetic characteristics of the participants. In addition, these drugs have limitations including low bioavailability, which results in insufficient plasma concentration levels. Additional studies on whole anti-cancer pathways and development strategies, including formulations, could result significant enhancements of the anti-cancer effects of benzimidazoles in clinical situations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While the doses used in this study were lower than those in the case series by Chiang et al. [1] (1 g/day, three times of week), FBZ still appears to be effective.”
From Fenbendazole as an Anticancer Agent? A Case Series of Self-Administration in Three Patients. (2025) · cites this paper as [1]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“To our knowledge, this is only the second case series documenting such outcomes after Stanford University Medical Center research group led by Chiang et al. [1] provided valuable insights into the potential repurposing of FBZ in cancer treatment.”
From Fenbendazole as an Anticancer Agent? A Case Series of Self-Administration in Three Patients. (2025) · cites this paper as [1]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Zhang, X., Zhao, J., Gao, X., Pei, D., & Gao, C. (2016) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2016.3992 · Cited by 41
RetractedSung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
New approaches and procedures for cancer treatment: Current perspectives
Debela, D. T., Muzazu, S. G., Heraro, K. D., Ndalama, M. T., Mesele, B. W., Haile, D. C., Kitui, S. K., & Manyazewal, T. (2021) · SAGE Open Medicine · doi:10.1177/20503121211034366 · Cited by 1,597
Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018
Wouters, O. J., McKee, M., & Luyten, J. (2020) · JAMA · doi:10.1001/jama.2020.1166 · Cited by 1,531
Overcoming cancer therapeutic bottleneck by drug repurposing
Zhang, Z., Zhou, L., Xie, N., Nice, E. C., Zhang, T., Cui, Y., & Huang, C. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00213-8 · Cited by 546
Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2016
Jung, K.-W., Won, Y.-J., Kong, H.-J., Lee, E. S., & Registries, T. C. O. P.-B. R. C. (2019) · Cancer Research and Treatment · doi:10.4143/crt.2019.138 · Cited by 392
Albendazole, mebendazole and praziquantel. Review of non-clinical toxicity and pharmacokinetics
Dayan, A. D. (2003) · Acta Tropica · doi:10.1016/s0001-706x(03)00031-7 · Cited by 371
Repurposing drugs in oncology (ReDO)—Cimetidine as an anti-cancer agent
Pantziarka, P. (2014) · ecancermedicalscience · doi:10.3332/ecancer.2014.485 · Cited by 280
The Out-of-Pocket Cost Burden of Cancer Care—A Systematic Literature Review
Iragorri, N., de Oliveira, C., Fitzgerald, N., & Essue, B. M. (2021) · Current Oncology · doi:10.3390/curroncol28020117 · Cited by 209
Research works printed but not linked: 1
- Kim, E.-Y. (2021, December 01). Dog Dewormer Goes Out of Stock Amid Rumor of Efficacy for Cancer. Korea Biomedical Review, 27 December 2019. Available online: https://www.koreabiomed.com/news/articleView.html?idxno=7073.
Cited by
Benzimidazole-Triazole Hybrids as Antimicrobial and Antiviral Agents: A Systematic Review
Marinescu, M. (2023) · Antibiotics · doi:10.3390/antibiotics12071220 · Cited by 127
Recent advances of benzimidazole as anticancer agents
Venugopal, S., Kaur, B., Verma, A., Wadhwa, P. K., Magan, M., Hudda, S., & Kakoty, V. (2023) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14236 · Cited by 67
Banerjee, S., Mukherjee, S., Nath, P., Mukherjee, A., Mukherjee, S., Kumar, S. K. A., De, S., & Banerjee, S. (2023) · Results in Chemistry · doi:10.1016/j.rechem.2023.101013 · Cited by 48
Mavvaji, M., & Akkoç, S. (2024) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2024.215714 · Cited by 46
Abbade, Y., Kışla, M. M., Hassan, M., Çelik, İ., Doğan, T. S., Mutlu, P., & Ateş‐Alagöz, Z. (2024) · ACS Omega · doi:10.1021/acsomega.3c09411 · Cited by 35
Metadata
- Authors
- Song, B., Park, E. Y., Kim, K. J., & Ki, S. H.
- Affiliations
- Chosun University (KR)
- Mokpo National University (KR)
- Corresponding author
- Kim, Kwang Joon
- Ki, Sung Hwan
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2022-09-22
- Volume
- 14
- Issue
- 19
- Pages
- 4601
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC9559625
- OpenAlex
- W4296992992
- Cited by
- 55
- References
- 104
- Citations by year
- 2026: 14 · 2025: 13 · 2024: 16 · 2023: 12
- FWCI
- 0.95
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Chosun University
- Topics
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
- Keywords
- benzimidazole anthelmintics, drug repurposing, anticancer activity, pharmacokinetics, bioavailability, clinical trials, drug formulation, antiparasitic drugs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Repurposing of Benzimidazole Anthelmintic Drugs as Cancer Therapeutics. https://app.cochat.ai/papers/10.3390/cancers14194601
- The paper
- Song, B., Park, E. Y., Kim, K. J., & Ki, S. H. (2022). Repurposing of Benzimidazole Anthelmintic Drugs as Cancer Therapeutics. Cancers. https://doi.org/10.3390/cancers14194601
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.